Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3892/etm.2020.8980 http://scihub22266oqcxt.onion/10.3892/etm.2020.8980 32765748!7401793!32765748     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Exp+Ther+Med 2020 ; 20 (3): 2557-2560 Nephropedia Template TP {{tp|p=32765748|t=2020. Pulmonary fibrosis in the aftermath of the COVID-19 era (Review) |pdf=|usr=}}{{32765748}} gab.com Text Pulmonary fibrosis in the aftermath of the COVID-19 era (Review) JO: Exp Ther Med http://www.kidney.de/pget.php?&tw=1&pmid=32765748 #FOAvip The year 2020 is characterized by the COVID-19 pandemic that has resulted in more than half a million deaths in recent months. The high mortality is associated with acute severe respiratory failure that results in ICU admission and intubation. While facing this fatal disease, research and clinical observations need to be carried out in order to evaluate the long-term effects of the COVID-19 acute respiratory distress syndrome (ARDS). Potent clinical and laboratory biomarkers should be studied to be able to predict the subgroup of patients that are going to deteriorate or develop lung fibrosis. The opportunity of personalized medicine is a good way to consider for these patients. Twit Text FOAVip Pulmonary fibrosis in the aftermath of the COVID-19 era (Review) ????Exp Ther Med http://www.kidney.de/pget.php?&tw=1&pmid=32765748 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32765748 #FOAvip English Wikipedia <ref>{{Cite pmid|32765748}}</ref> Pulmonary fibrosis in the aftermath of the COVID-19 era (Review) #MMPMID32765748 Vasarmidi E; Tsitoura E; Spandidos DA; Tzanakis N; Antoniou KM Exp Ther Med 2020[Sep]; 20 (3): 2557-2560 PMID32765748show ga The year 2020 is characterized by the COVID-19 pandemic that has resulted in more than half a million deaths in recent months. The high mortality is associated with acute severe respiratory failure that results in ICU admission and intubation. While facing this fatal disease, research and clinical observations need to be carried out in order to evaluate the long-term effects of the COVID-19 acute respiratory distress syndrome (ARDS). Potent clinical and laboratory biomarkers should be studied to be able to predict the subgroup of patients that are going to deteriorate or develop lung fibrosis. The opportunity of personalized medicine is a good way to consider for these patients. äPulmonary fibrosis in the aftermath of the COVID-19 era (Review) (epmc).pdf DeepDyve Pubget Overpricing